Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Arterioscler Thromb Vasc Biol. 2011 Apr;31(4):814-20. doi: 10.1161/ATVBAHA.110.219980. Epub 2011 Jan 13.
The G-protein-coupled receptor APJ and its ligand apelin are highly expressed in the pulmonary vasculature, but their function in this vascular bed is unclear. We hypothesized that disruption of apelin signaling would lead to worsening of the vascular remodeling associated with pulmonary hypertension (PH).
We found that apelin-null mice developed more severe PH compared with wild-type mice when exposed to chronic hypoxia. Micro-computed tomography of the pulmonary arteries demonstrated significant pruning of the microvasculature in the apelin-null mice. Apelin-null mice had a significant reduction of serum nitrate levels. This was secondary to downregulation of endothelial nitric oxide synthase (eNOS), which was associated with reduced expression of Kruppel-like factor 2 (KLF2), a known regulator of eNOS expression. In vitro knockdown studies targeting apelin in human pulmonary artery endothelial cells demonstrated decreased eNOS and KLF2 expression, as well as impaired phosphorylation of AMP-activated kinase and eNOS. Moreover, serum apelin levels of patients with PH were significantly lower than those of controls.
These data demonstrate that disruption of apelin signaling can exacerbate PH mediated by decreased activation of AMP-activated kinase and eNOS, and they identify this pathway as a potentially important therapeutic target for treatment of this refractory human disease.
G 蛋白偶联受体 APJ 及其配体 Apelin 在肺血管中高度表达,但它们在该血管床中的功能尚不清楚。我们假设 Apelin 信号的破坏会导致与肺动脉高压(PH)相关的血管重构恶化。
我们发现,与野生型小鼠相比,慢性缺氧暴露时 Apelin 缺失小鼠发生更严重的 PH。肺小动脉的微计算机断层扫描显示 Apelin 缺失小鼠的微血管明显修剪。Apelin 缺失小鼠的血清硝酸盐水平显著降低。这是内皮型一氧化氮合酶(eNOS)下调的结果,这与已知的 eNOS 表达调节剂 Kruppel 样因子 2(KLF2)的表达减少有关。针对人肺血管内皮细胞中的 Apelin 的体外敲低研究表明,eNOS 和 KLF2 的表达减少,以及 AMP 激活的蛋白激酶和 eNOS 的磷酸化受损。此外,PH 患者的血清 Apelin 水平明显低于对照组。
这些数据表明,Apelin 信号的破坏会加剧由 AMP 激活的蛋白激酶和 eNOS 活性降低介导的 PH,并将该途径确定为治疗这种难治性人类疾病的潜在重要治疗靶点。